GNLX
NASDAQGenelux Corporation
News · 26 weeks44+100%
2025-12-282026-06-21
Mix2490d
- Insider19(79%)
- SEC Filings4(17%)
- Other1(4%)
Latest news
25 items- SECSEC Form 8-K filed by Genelux Corporation8-K - GENELUX Corp (0001231457) (Filer)
- INSIDERPresident and CEO Zindrick Thomas was granted 730,601 shares, increasing direct ownership by 137% to 1,263,913 units (SEC Form 4)4 - GENELUX Corp (0001231457) (Issuer)
- INSIDERGeneral Counsel Groen Eric was granted 233,957 shares (SEC Form 4)4 - GENELUX Corp (0001231457) (Issuer)
- INSIDERDirector Thomas John was granted 28,409 shares, increasing direct ownership by 6% to 501,193 units (SEC Form 4)4 - GENELUX Corp (0001231457) (Issuer)
- INSIDERChief Financial Officer Pulisic Matthew was granted 278,906 shares (SEC Form 4)4 - GENELUX Corp (0001231457) (Issuer)
- INSIDERDirector Tyree James L was granted 28,409 shares, increasing direct ownership by 42% to 96,483 units (SEC Form 4)4 - GENELUX Corp (0001231457) (Issuer)
- INSIDERChief Technical Officer Cappello Joseph was granted 174,841 shares, increasing direct ownership by 113% to 329,390 units (SEC Form 4)4 - GENELUX Corp (0001231457) (Issuer)
- INSIDERDirector Smither John W was granted 28,409 shares, increasing direct ownership by 38% to 103,403 units (SEC Form 4)4 - GENELUX Corp (0001231457) (Issuer)
- INSIDERDirector Mirabelli Mary was granted 28,409 shares, increasing direct ownership by 38% to 102,693 units (SEC Form 4)4 - GENELUX Corp (0001231457) (Issuer)
- INSIDERChief Scientific Officer Yu Yong was granted 119,318 shares, increasing direct ownership by 80% to 269,024 units (SEC Form 4)4 - GENELUX Corp (0001231457) (Issuer)
- INSIDERHead of Regulatory Smalling Ralph sold $563 worth of shares (192 units at $2.93), decreasing direct ownership by 0.28% to 67,611 units (SEC Form 4)4 - GENELUX Corp (0001231457) (Issuer)
- INSIDERDirector Thomas John sold $29,801 worth of shares (10,000 units at $2.98) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 472,784 units (SEC Form 4)4 - GENELUX Corp (0001231457) (Issuer)
- INSIDERChief Technical Officer Cappello Joseph sold $1,799 worth of shares (605 units at $2.97), decreasing direct ownership by 0.39% to 154,549 units (SEC Form 4)4 - GENELUX Corp (0001231457) (Issuer)
- INSIDERChief Scientific Officer Yu Yong sold $1,798 worth of shares (605 units at $2.97), decreasing direct ownership by 0.40% to 149,706 units (SEC Form 4)4 - GENELUX Corp (0001231457) (Issuer)
- INSIDERHead of Regulatory Smalling Ralph sold $804 worth of shares (270 units at $2.98), decreasing direct ownership by 0.40% to 67,803 units (SEC Form 4)4 - GENELUX Corp (0001231457) (Issuer)
- INSIDERPresident and CEO Zindrick Thomas sold $8,226 worth of shares (2,798 units at $2.94), decreasing direct ownership by 0.52% to 532,051 units (SEC Form 4)4 - GENELUX Corp (0001231457) (Issuer)
- PRGenelux Corporation Reports First Quarter Financial Results and Provides Business Updates-- Topline data from randomized Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Systemic lung cancer programs advancing with additional updates expected throughout 2026 -- -- $26.3 million in cash, cash equivalents, marketable securities and restricted cash as of March 31, 2026; expected to fund operations into 1Q27 -- WESTLAKE VILLAGE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2026 and provided general business updates. "As we build on our momentum entering 2026, we remain focused on disciplined exec
- SECSEC Form 10-Q filed by Genelux Corporation10-Q - GENELUX Corp (0001231457) (Filer)
- SECSEC Form DEFA14A filed by Genelux CorporationDEFA14A - GENELUX Corp (0001231457) (Filer)
- SECSEC Form DEF 14A filed by Genelux CorporationDEF 14A - GENELUX Corp (0001231457) (Filer)
- INSIDERSEC Form 4 filed by Zindrick Thomas4 - GENELUX Corp (0001231457) (Issuer)
- INSIDERSEC Form 4 filed by Smalling Ralph4 - GENELUX Corp (0001231457) (Issuer)
- INSIDERSEC Form 4 filed by Yu Yong4 - GENELUX Corp (0001231457) (Issuer)
- INSIDERSEC Form 4 filed by Cappello Joseph4 - GENELUX Corp (0001231457) (Issuer)
- SECSEC Form 424B5 filed by Genelux Corporation424B5 - GENELUX Corp (0001231457) (Filer)
GNLX FAQ
6 questionsWhere does GNLX stock trade?
Genelux Corporation (GNLX) is listed on NASDAQ.What sector and industry is GNLX in?
Genelux Corporation operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Genelux Corporation go public?
Genelux Corporation (GNLX) completed its IPO in 2023.What are analysts saying about GNLX?
Genelux Corporation has had 6 recent analyst actions on file. The most recent action was from Lake Street: Buy with a $1600.00 price target on 2025-10-21. Recent price targets range from $800.00 to $4000.00.What companies are similar to GNLX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare GNLX side-by-side with any of them on Quantisnow.How can I track GNLX on Quantisnow?
Quantisnow aggregates Genelux Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GNLX to receive live email and push alerts on every new disclosure.